Sana Biotechnology Announces FDA Clearance oOf Investigational New Drug Application For SC291, A Hypoimmune-Modified, CD19-Directed Allogeneic CAR T Therapy, For Patients With Lupus Nephritis, Extrarenal Lupus, And ANCA-Associated Vasculitis
Benzinga Newsdesk - Nov 9, 2023, 5:28PM